Summit Hotel Properties, Inc. (INN): Price and Financial Metrics
INN Price/Volume Stats
Current price | $5.54 | 52-week high | $8.81 |
Prev. close | $5.62 | 52-week low | $5.42 |
Day low | $5.54 | Volume | 364,417 |
Day high | $5.62 | Avg. volume | 806,988 |
50-day MA | $5.91 | Dividend yield | 4.22% |
200-day MA | $6.83 | Market Cap | 595.98M |
INN Stock Price Chart Interactive Chart >
INN POWR Grades
- INN scores best on the Momentum dimension, with a Momentum rank ahead of 61.04% of US stocks.
- The strongest trend for INN is in Stability, which has been heading up over the past 179 days.
- INN ranks lowest in Quality; there it ranks in the 11th percentile.
INN Stock Summary
- Of note is the ratio of SUMMIT HOTEL PROPERTIES INC's sales and general administrative expense to its total operating expenses; merely 3.91% of US stocks have a lower such ratio.
- In terms of twelve month growth in earnings before interest and taxes, SUMMIT HOTEL PROPERTIES INC is reporting a growth rate of 82.41%; that's higher than 86.33% of US stocks.
- SUMMIT HOTEL PROPERTIES INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 15.94%, greater than the shareholder yield of 88.89% of stocks in our set.
- Stocks that are quantitatively similar to INN, based on their financial statements, market capitalization, and price volatility, are PDM, CUZ, PLYM, GMRE, and NOG.
- Visit INN's SEC page to see the company's official filings. To visit the company's web site, go to www.shpreit.com.
INN Valuation Summary
- INN's price/sales ratio is 0.9; this is 25% lower than that of the median Real Estate stock.
- INN's EV/EBIT ratio has moved down 298.5 over the prior 153 months.
Below are key valuation metrics over time for INN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
INN | 2023-09-15 | 0.9 | 0.7 | -33.5 | 25.4 |
INN | 2023-09-14 | 0.8 | 0.6 | -32.9 | 25.3 |
INN | 2023-09-13 | 0.8 | 0.6 | -32.8 | 25.3 |
INN | 2023-09-12 | 0.9 | 0.7 | -33.8 | 25.5 |
INN | 2023-09-11 | 0.9 | 0.7 | -34.4 | 25.6 |
INN | 2023-09-08 | 0.9 | 0.7 | -34.3 | 25.6 |
INN Growth Metrics
- The 4 year net cashflow from operations growth rate now stands at -12.82%.
- Its 2 year cash and equivalents growth rate is now at -27.92%.
- Its 5 year cash and equivalents growth rate is now at 67.95%.

The table below shows INN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 610.231 | 151.443 | -20.227 |
2022-06-30 | 542.665 | 138.124 | -30.674 |
2022-03-31 | 445.941 | 94.723 | -61.019 |
2021-12-31 | 361.926 | 66.051 | -83.714 |
2021-09-30 | 303.294 | 29.628 | -115.203 |
2021-06-30 | 245.02 | -6.391 | -142.495 |
INN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- INN has a Quality Grade of D, ranking ahead of 9.47% of graded US stocks.
- INN's asset turnover comes in at 0.136 -- ranking 136th of 444 Trading stocks.
- CLDT, APLE, and CDOR are the stocks whose asset turnover ratios are most correlated with INN.
The table below shows INN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.136 | 0.413 | -0.016 |
2021-06-30 | 0.109 | 0.371 | -0.026 |
2021-03-31 | 0.081 | 0.296 | -0.035 |
2020-12-31 | 0.101 | 0.336 | -0.029 |
2020-09-30 | 0.136 | 0.392 | -0.013 |
2020-06-30 | 0.172 | 0.423 | 0.000 |
INN Price Target
For more insight on analysts targets of INN, see our INN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $11.67 | Average Broker Recommendation | 1.58 (Moderate Buy) |
Summit Hotel Properties, Inc. (INN) Company Bio
Summit Hotel Properties, Inc. engages in acquiring, owning, renovating, repositioning, and asset-managing and selling premium-branded limited-service and select-service hotels in the upscale and midscale without food and beverage segments of the United States lodging industry. The company was founded in 2004 and is based in Sioux Falls, South Dakota.
Latest INN News From Around the Web
Below are the latest news stories about SUMMIT HOTEL PROPERTIES INC that investors may wish to consider to help them evaluate INN as an investment opportunity.
Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory BoardInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology company specializing in innovative wellness products, is elated to announce the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain management and critical care medicine, will be instrumental in the Company's upcoming planned FDA filing for human medications. |
SUMMIT HOTEL PROPERTIES PUBLISHES 2023 CORPORATE RESPONSIBILITY REPORTSummit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced the publication of its annual Corporate Responsibility Report for 2023, which presents the Company's ongoing commitment to creating long-term value for the business and industry by investing responsibly in safeguarding the environment and supporting its employees, communities, and other stakeholders. |
Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy TestInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its hair care cream (the "Product"). |
Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD InjectionInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the results of a clinical study regarding the pain-relieving effects and safety of the Company's subcutaneous liposomal CBD (Innocan's LPT platform) for dogs with osteoarthritis. Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine" (the "Study"). The Study highlights that CBD plasma levels were dete |
Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and six months period ended June 30, 2023. |
INN Price Returns
1-mo | -1.25% |
3-mo | -7.91% |
6-mo | -12.83% |
1-year | -23.94% |
3-year | 9.98% |
5-year | -52.87% |
YTD | -21.38% |
2022 | -25.33% |
2021 | 8.32% |
2020 | -25.87% |
2019 | 34.95% |
2018 | -32.54% |
INN Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching INN
Want to see what other sources are saying about Summit Hotel Properties Inc's financials and stock price? Try the links below:Summit Hotel Properties Inc (INN) Stock Price | Nasdaq
Summit Hotel Properties Inc (INN) Stock Quote, History and News - Yahoo Finance
Summit Hotel Properties Inc (INN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...